查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933904

按產品類型、手術類型、材料、最終用戶和臨床適應症分類的血管重建器械市場—全球預測，2026-2032年

Revascularization Device Market by Product Type, Procedure Type, Material, End User, Clinical Indication - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，再灌注設備市場價值將達到 25.7 億美元，到 2026 年將成長至 28.3 億美元，到 2032 年將達到 51.2 億美元，年複合成長率為 10.30%。

關鍵市場統計數據
基準年 2025 25.7億美元
預計年份：2026年 28.3億美元
預測年份 2032 51.2億美元
複合年成長率 (%) 10.30%

日益成長的臨床、監管和技術壓力如何重塑現代醫療路徑中再灌注裝置的研發和臨床應用

再灌注器材領域正處於不斷發展的臨床實踐、技術改進和不斷變化的監管重點的交匯點。臨床醫生越來越傾向於採用微創方法，以減少手術創傷並保持血管完整性，而器械開發商則透過改進支架平台、生物可吸收支架和輔助導管技術來響應這一需求，這些技術強調輸送性和長期血管癒合。同時，支付方的嚴格審查和以價值為導向的醫療模式也對製造商和醫療系統提出了挑戰，要求他們證明其產品能夠提供持續的臨床療效和具有成本效益的治療方案。

材料科學的進步、影像導引手術以及不斷擴大的門診護理正在共同重新定義設備創新重點和臨床應用模式。

再灌注裝置領域正經歷變革性的轉變，這得益於材料科學的突破、手術技術的進步以及對以患者為中心的治療效果日益成長的需求。聚合物化學和金屬合金工程的進步使得支架結構更加纖細，藥物釋放型動力學更可預測，進而影響血管再阻塞情況和血管癒合。同時，血管內影像和生理評估的整合正在改變外科醫生規劃和實施手術的方式，推動決策模式從單純依賴血管造影術轉向精準引導下的支架放置和尺寸選擇。

關稅驅動的供應鏈重組和近岸外包措施導致設備製造商的營運中斷和策略採購重新評估。

2025年，美國關稅的累積影響相關人員帶來了新的商業性複雜性。關稅加劇了採購和庫存計劃的成本壓力，迫使製造商重新評估其籌資策略，並在免稅地區尋找替代供應商。因此，許多機構開始著手繪製供應鏈圖，以識別關稅風險，並優先考慮與全球供應商重新談判合約。

為什麼將產品、流程、材料、最終用戶和適應症細分整合到您的商業化策略中對於臨床應用和持續相關性至關重要

細分市場分析揭示了按產品類型、最終用戶、手術類型、材料和臨床適應症分類的各類產品，其開發和商業化路徑各不相同。產品類型分類包括動脈粥狀硬化斑塊切除術裝置、球囊血管成形術導管、裸金屬支架、藥物塗層球囊、藥物釋放型支架和血管支架。藥物釋放型支架又細分為依Everolimus洗脫支架、Sirolimus洗脫支架、西羅莫司洗脫支架和佐他莫司洗脫支架，每個亞組都有其獨特的臨床權衡和監管過程，這些都會影響其市場推廣路徑。以最終用戶分類，器械的使用模式主要集中在門診手術中心、醫院和專科醫療中心，這些管道對物流和採購的要求各不相同，從而影響產品設計和支援模式。

美洲、歐洲、中東和非洲以及亞太地區的區域監管、臨床和商業性趨勢如何影響市場進入和推廣路徑，並針對每個市場量身定做這些路徑。

區域趨勢對臨床實踐模式、監管路徑和商業化策略有著顯著影響，美洲、歐洲、中東和非洲以及亞太地區各有其獨特的策略要務。在美洲，成熟的介入性心臟病學網路和整合的支付系統強調強力的臨床證據和已證實的價值，製造商通常優先考慮廣泛的上市後監測和臨床醫生培訓項目，以支持產品在醫院和門診管道的持續應用。而在歐洲和中東及非洲地區，由於監管環境的多樣性和報銷機制的不均衡，需要更精細的市場進入策略，以適應各國採購慣例實踐和區域臨床指南的差異。

再灌注裝置的競爭優勢源自於整合研發、持續的臨床證據以及降低市場進入門檻的策略夥伴關係。

血管重建器材領域的競爭格局由成熟的平台供應商、專業創新企業和垂直整合供應商組成，它們各自在器材設計、實證醫學證據產生和醫療服務提供者合作方面採取差異化策略。現有企業傾向於逐步改善平台、拓展臨床適應症，並提供包括技術培訓和長期監測計畫在內的綜合服務。同時，專業創新企業則優先開發材料創新、新型藥物釋放型基質和手術輔助器械，旨在解決尚未滿足的臨床挑戰，例如複雜病變形態和高出血風險患者群體。

為醫療設備製造商提供切實可行的策略性舉措，以加速產品推廣應用、增強市場韌性，並建立符合醫療機構臨床和支付方期望的證據。

產業領導者應優先考慮一系列切實可行的措施，使產品開發與臨床實際情況和商業性需求保持一致。首先，加快轉化醫學項目，將材料最佳化與具有臨床意義的終點指標和可操作的註冊研究設計相結合，以產生能夠引起介入醫師和支付方共鳴的證據。其次，透過近岸外包和關鍵零件的多通路籌資策略，投資供應鏈韌性，同時維持嚴格的變更管理流程，以最大限度地減少監管摩擦。第三，制定針對最終使用者環境的商業化方案，針對每個部署情境（門診手術中心、醫院和專科醫療中心）設計訓練、包裝和支援方法。

採用嚴謹的混合方法，結合臨床醫生訪談、監管和臨床文獻的綜合分析以及供應鏈分析，以形成可操作的見解和檢驗的細分框架。

本研究結合了對臨床醫生、採購專業人員和行業高管的定性訪談，並輔以對同行評審文獻、監管文件和臨床註冊資料進行的二次分析，以確保證據的全面性。訪談重點在於手術流程、裝置選擇標準和術後追蹤實踐，而二次分析則著重於材料性能特徵、監管指導文件以及已發表的安全性和有效性文獻。調查方法強調多資訊來源驗證，以檢驗主題結論並減少單一資訊來源偏差。

整合臨床、技術和商業性的必要因素，以確定將器材創新轉化為持續臨床影響的策略重點。

總之，再灌注裝置領域正經歷技術快速進步、臨床工作流程不斷演變以及對長期價值日益成長的需求。材料創新、影像整合以及門診手術的普及正在改變裝置的設計、評估和使用方式。供應鏈中斷和關稅壓力凸顯了穩健籌資策略的重要性以及組件採購的實際影響，而監管和支付框架的區域差異則要求制定適應性強的市場進入計劃。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的血管重建器械市場

  • 動脈粥狀硬化斑塊切除術裝置
  • 球囊血管成形術導管
  • 裸金屬支架
  • 藥物塗層球囊
  • 藥物釋放型支架
    • Everolimus洗脫支架
    • 紫杉醇洗脫支架
    • Sirolimus洗脫支架
    • 佐他莫司洗脫支架
  • 血管支架

9. 依手術方式分類的血管重建器械市場

  • 冠狀動脈繞道手術手術
  • 經皮冠狀動脈介入治療

第10章 血管再生設備市場（依材料分類）

  • 生物可吸收支架
  • 由金屬製成
    • 鈷鉻
    • 鉑金鉻
    • 不銹鋼
  • 聚合物
    • 生物可吸收聚合物
    • 不可生物分解聚合物

第11章 依最終用戶分類的血管重建器械市場

  • 門診手術中心
  • 醫院
  • 專業醫療中心

第12章 依疾病分類的血管重建器械市場

  • 急性冠狀動脈症候群
  • 血管再阻塞
  • 穩定性冠狀動脈疾病

第13章 區域性血管重建器械市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 血管重建器械市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國血管重建器械市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國血管重建器械市場

第17章：中國血管再生設備市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AngioDynamics, Inc.
  • Asahi Intecc Co., Ltd.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Cook Medical LLC
  • Edwards Lifesciences Corporation
  • Getinge AB
  • iVascular SLU
  • Johnson & Johnson
  • Lepu Medical Technology（Beijing）Co., Ltd
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • MicroPort Scientific Corporation
  • OrbusNeich Medical Company Limited
  • Penumbra, Inc.
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Corporation
  • WL Gore & Associates, Inc.
Product Code: MRR-C36616F699B7

The Revascularization Device Market was valued at USD 2.57 billion in 2025 and is projected to grow to USD 2.83 billion in 2026, with a CAGR of 10.30%, reaching USD 5.12 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.57 billion
Estimated Year [2026] USD 2.83 billion
Forecast Year [2032] USD 5.12 billion
CAGR (%) 10.30%

How converging clinical, regulatory, and technological pressures are reshaping revascularization device development and clinical adoption across contemporary care pathways

The revascularization devices landscape sits at the intersection of evolving clinical practice, technological refinement, and shifting regulatory priorities. Clinicians increasingly favor minimally invasive approaches that reduce procedural trauma while preserving vessel integrity, and device innovators respond with refined stent platforms, bioabsorbable scaffolds, and adjunctive catheter technologies that emphasize deliverability and long-term vessel healing. Concurrently, payer scrutiny and value-based care initiatives prompt manufacturers and health systems to demonstrate durable clinical outcomes and cost-effective pathways.

In this context, multidisciplinary teams are adapting pathways that blend interventional cardiology expertise with advanced imaging and adjunctive therapies to optimize patient selection and procedural outcomes. As a result, product development priorities have migrated from incremental mechanical improvements toward integrated systems that consider material composition, drug elution profiles, and procedural efficiency. Regulatory agencies have intensified focus on real-world safety data and post-market surveillance, driving manufacturers to incorporate robust evidence-generation plans into their clinical development strategies.

Taken together, these dynamics create a responsive but complex environment in which new entrants must navigate clinical credibility, supply chain resilience, and health-economics signaling. Therefore, stakeholders are increasingly prioritizing translational evidence, clinical partnerships, and strategic commercialization pathways to convert innovation into sustainable clinical adoption and durable patient benefit.

Material science improvements, imaging-guided procedures, and outpatient care expansion are collectively redefining device innovation priorities and clinical utilization patterns

The revascularization device landscape is undergoing transformative shifts driven by a combination of material science breakthroughs, procedural technique evolution, and heightened demand for patient-centric outcomes. Advances in polymer chemistry and metallic alloy engineering have enabled thinner strut profiles and more predictable drug-elution kinetics, which in turn influence restenosis profiles and vessel healing. Meanwhile, the integration of intravascular imaging and physiologic assessment is changing how operators plan and execute interventions, prompting a move away from angiography-alone decision making toward precision-guided placement and sizing.

At the same time, the rise of ambulatory surgical centers and outpatient procedural pathways is encouraging device manufacturers to design systems optimized for simplified logistics, shorter procedure times, and reduced anesthesia requirements. Concurrently, iterative improvements in atherectomy and balloon technologies are expanding the procedural toolkit for complex lesion preparation, facilitating the use of contemporary stents and scaffolds in anatomies that were previously challenging. Collectively, these shifts foster a more patient-centered approach that privileges device performance in realistic clinical settings, and they require manufacturers to align product portfolios with evolving care delivery models and clinician preferences for evidence-backed innovations.

Furthermore, reimbursement and regulatory expectations are increasingly tethered to demonstrable long-term safety and economic value, prompting a surge in registries and pragmatic trials. As a result, organizations that can bridge bench advances with robust clinical evidence and efficient commercial strategies will maintain competitive advantage in this rapidly adapting environment.

Tariff-driven supply chain realignment and nearshoring initiatives created operational disruption and strategic procurement recalibrations across device manufacturers

In 2025, the cumulative effects of tariff measures in the United States introduced a new layer of commercial complexity for revascularization device stakeholders who rely on global supply chains for components, raw materials, and finished goods. Tariff measures amplified cost pressure across procurement and inventory planning, prompting manufacturers to reassess sourcing strategies and to explore alternative suppliers in tariff-exempt jurisdictions. As a consequence, many organizations initiated supply-chain mapping exercises to identify tariff exposure points and to prioritize contractual renegotiations with global vendors.

Operationally, the tariffs accelerated conversations about nearshoring and supplier diversification. Several manufacturers pursued incremental localization of critical manufacturing steps, particularly for metallic substrates and polymer processing, to reduce exposure to cross-border levies and associated lead-time volatility. Simultaneously, procurement teams increased focus on total landed cost analyses that incorporate tariff liabilities, customs clearance complexities, and potential disruption risks. Importantly, while tariffs affected transactional cost dynamics, clinical adoption decisions continued to hinge on safety, efficacy, and long-term outcomes, meaning that commercial repositioning required careful communication to payers and providers about any product or packaging changes.

In parallel, regulatory filings and quality documentation underwent closer scrutiny when supply chain changes were implemented, since component substitutions and manufacturing site shifts can trigger additional regulatory interactions. Thus, tariffs contributed to a strategic rebalancing across procurement, quality, regulatory, and commercial functions, emphasizing resilience and transparency in supplier relationships and manufacturing plans.

Why integrating product, procedural, material, end-user, and indication segmentation into commercialization strategies is critical for clinical uptake and sustained relevance

Segmentation analysis reveals distinct pathways for product development and commercialization across categories defined by product type, end user, procedure type, material, and clinical indication. Based on Product Type, the landscape is organized around Atherectomy Devices, Balloon Angioplasty Catheters, Bare-Metal Stents, Drug-Coated Balloons, Drug-Eluting Stents, and Vascular Scaffolds, with the Drug-Eluting Stents cohort further subdivided into Everolimus-Eluting Stents, Paclitaxel-Eluting Stents, Sirolimus-Eluting Stents, and Zotarolimus-Eluting Stents, each subgroup presenting unique clinical trade-offs and regulatory histories that influence adoption pathways. Based on End User, device utilization patterns concentrate in Ambulatory Surgical Center, Hospital, and Specialty Center settings, and these channels impose different logistical and purchasing requirements that affect product design and support models.

Based on Procedure Type, stakeholders must align product claims and training efforts to the clinical nuances of Coronary Artery Bypass Grafting versus Percutaneous Coronary Intervention, as procedural complexity and operator workflows diverge significantly between surgical revascularization and catheter-based approaches. Based on Material, device performance and long-term vessel response are shaped by choices among Bioabsorbable Scaffold, Metallic, and Polymer compositions, with Metallic constructs further differentiated by Cobalt-Chromium, Platinum-Chromium, and Stainless Steel alloys, and Polymer options distinguished between Bioresorbable Polymer and Non-Biodegradable Polymer approaches that carry distinct healing and surveillance considerations. Based on Clinical Indication, device selection is influenced by the clinical presentation, whether Acute Coronary Syndrome, Restenosis, or Stable Coronary Artery Disease, and these indications drive both procedural urgency and evidence expectations.

Taken together, the segmentation framework highlights that a one-size-fits-all commercialization strategy is unlikely to succeed. Instead, targeted development plans that account for clinical context, material science implications, and health system purchasing behavior will be essential to achieve clinical uptake and to sustain long-term relevance in varied care settings.

How region-specific regulatory, clinical, and commercial dynamics in the Americas, Europe Middle East & Africa, and Asia-Pacific shape tailored market access and adoption pathways

Regional dynamics exert powerful influence on clinical practice patterns, regulatory pathways, and commercialization approaches, with distinct strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, established interventional cardiology networks and consolidated payer systems emphasize robust clinical evidence and value demonstration, and manufacturers often prioritize extensive post-market studies and clinician training programs to support durable adoption across hospital and outpatient channels. Conversely, in Europe, Middle East & Africa, diverse regulatory frameworks and heterogeneous reimbursement landscapes require more nuanced market access strategies that adapt to country-level procurement conventions and regional clinical guideline variations.

In the Asia-Pacific region, rapid infrastructural investments in tertiary care and increasing procedural volumes create fertile ground for scalable deployment, yet manufacturers must tailor product portfolios to local clinical preferences, cost sensitivities, and regulatory timelines. Moreover, cross-border partnerships and capacity-building initiatives often accelerate adoption when local champions and opinion leaders validate new device paradigms. Throughout these regions, connectivity among supply chain considerations, clinical evidence generation, and commercialization execution remains central. Therefore, organizations that calibrate clinical data programs, regulatory submissions, and commercial support to each region's specific operating environment will be better positioned to translate innovation into consistent clinical use and operational sustainability.

Competitive positioning in revascularization devices rewards integrated R&D, clinical evidence alignment, and strategic partnerships that lower adoption barriers

The competitive landscape in revascularization devices is populated by established platform providers, specialized innovators, and a cadre of vertically integrated suppliers, each pursuing differentiated strategies in device design, evidence generation, and provider engagement. Incumbent organizations often focus on incremental platform improvements, expanded clinical indications, and bundled service offerings that include technical training and long-term surveillance programs. In contrast, specialized innovators prioritize material innovation, novel drug-elution matrices, and procedural adjuncts that seek to resolve unmet clinical challenges such as complex lesion morphology or high-bleeding-risk populations.

Across the competitive set, strategic partnerships between device developers and technology providers-particularly in imaging, data analytics, and remote proctoring-have emerged as a key vector for differentiation. These alliances facilitate combined value propositions that address both procedural efficacy and operational efficiency. Moreover, the interplay between intellectual property strength, manufacturing footprint, and regulatory acumen determines how rapidly organizations can translate laboratory advances into clinical availability. Consequently, competitive advantage increasingly accrues to entities that synchronize R&D pipelines with robust clinical programs and pragmatic commercialization models that reduce adoption friction for providers.

Practical strategic initiatives for device manufacturers to accelerate adoption, enhance resilience, and align evidence with clinical and payer expectations across care settings

Industry leaders should prioritize a set of actionable initiatives that align product development with clinical realities and commercial imperatives. First, accelerate translational programs that combine material optimization with clinically meaningful endpoints and pragmatic registry designs to generate evidence that resonates with interventionalists and payers. Second, invest in supply chain resilience through nearshoring or multi-sourcing strategies for critical components while maintaining rigorous change-control processes to minimize regulatory friction. Third, tailor commercialization playbooks to end-user settings by designing training, packaging, and support modalities specifically for Ambulatory Surgical Center, Hospital, and Specialty Center adoption scenarios.

In addition, embed imaging and physiologic guidance into product value narratives to demonstrate how devices integrate into precision-guided procedural workflows. Align clinical indication planning to address Acute Coronary Syndrome, Restenosis, and Stable Coronary Artery Disease use cases with distinct evidence strategies and post-market surveillance commitments. Finally, pursue selective regional approaches that account for regulatory and payer landscapes in the Americas, Europe, Middle East & Africa, and Asia-Pacific, leveraging local clinical champions and adaptive reimbursement strategies to facilitate market entry and sustained utilization. By implementing these initiatives, organizations can reduce time-to-adoption, enhance clinician confidence, and create compelling value propositions for diverse stakeholder groups.

A rigorous mixed-methods approach combining clinician interviews, regulatory and clinical literature synthesis, and supply-chain analysis to produce actionable insights and validated segmentation frameworks

This research synthesized primary qualitative interviews with clinicians, procurement specialists, and industry executives, supplemented by secondary source analysis of peer-reviewed literature, regulatory documents, and clinical registry outputs to ensure a comprehensive evidence base. Primary interviews focused on procedural workflow, device selection criteria, and post-procedural follow-up practices, while secondary analysis emphasized material performance characteristics, regulatory guidance documents, and published safety and efficacy literature. The methodology emphasized triangulation across sources to validate thematic conclusions and to reduce single-source bias.

Data curation and categorization adhered to rigorous inclusion criteria for clinical relevance and methodological transparency. Device categorizations and segmentation frameworks were developed in consultation with clinical advisors to ensure that product, material, procedural, and indication groupings reflected current practice patterns. Furthermore, supply chain and commercial impact assessments were informed by procurement and operations interviews, enabling a practical view of tariff and sourcing implications. Analytical limitations included potential regional variability in data availability and the evolving nature of post-market evidence, which were addressed through targeted sensitivity checks and iterative review with subject-matter experts. Overall, the approach combined depth of clinical insight with operational and commercial analysis to produce actionable conclusions for stakeholders.

Synthesis of clinical, technological, and commercial imperatives that define strategic priorities for converting device innovation into durable clinical impact

In conclusion, the revascularization device environment is characterized by rapid technical refinement, evolving clinical workflows, and intensified demands for demonstrable long-term value. Material innovations, imaging integration, and outpatient procedural expansion are reshaping how devices are designed, evaluated, and utilized. Supply-chain perturbations and tariff-related pressures have underscored the importance of resilient procurement strategies and the operational implications of component sourcing, while regional differences in regulatory and payer frameworks necessitate adaptive market access plans.

Therefore, stakeholders who synchronize product innovation with pragmatic evidence programs, robust quality and regulatory planning, and targeted commercialization tactics will be best positioned to succeed. Emphasizing clinician collaboration, selective regional prioritization, and transparent communication about safety and performance will facilitate adoption and foster trust among providers and payers alike. As the field continues to evolve, organizations that internalize these priorities and maintain nimble execution will convert technological advances into sustained clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Revascularization Device Market, by Product Type

  • 8.1. Atherectomy Devices
  • 8.2. Balloon Angioplasty Catheters
  • 8.3. Bare-Metal Stents
  • 8.4. Drug-Coated Balloons
  • 8.5. Drug-Eluting Stents
    • 8.5.1. Everolimus-Eluting Stents
    • 8.5.2. Paclitaxel-Eluting Stents
    • 8.5.3. Sirolimus-Eluting Stents
    • 8.5.4. Zotarolimus-Eluting Stents
  • 8.6. Vascular Scaffolds

9. Revascularization Device Market, by Procedure Type

  • 9.1. Coronary Artery Bypass Grafting
  • 9.2. Percutaneous Coronary Intervention

10. Revascularization Device Market, by Material

  • 10.1. Bioabsorbable Scaffold
  • 10.2. Metallic
    • 10.2.1. Cobalt-Chromium
    • 10.2.2. Platinum-Chromium
    • 10.2.3. Stainless Steel
  • 10.3. Polymer
    • 10.3.1. Bioresorbable Polymer
    • 10.3.2. Non-Biodegradable Polymer

11. Revascularization Device Market, by End User

  • 11.1. Ambulatory Surgical Center
  • 11.2. Hospital
  • 11.3. Specialty Center

12. Revascularization Device Market, by Clinical Indication

  • 12.1. Acute Coronary Syndrome
  • 12.2. Restenosis
  • 12.3. Stable Coronary Artery Disease

13. Revascularization Device Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Revascularization Device Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Revascularization Device Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Revascularization Device Market

17. China Revascularization Device Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AngioDynamics, Inc.
  • 18.7. Asahi Intecc Co., Ltd.
  • 18.8. B. Braun Melsungen AG
  • 18.9. Becton, Dickinson and Company
  • 18.10. Biotronik SE & Co. KG
  • 18.11. Boston Scientific Corporation
  • 18.12. Cardinal Health, Inc.
  • 18.13. Cook Medical LLC
  • 18.14. Edwards Lifesciences Corporation
  • 18.15. Getinge AB
  • 18.16. iVascular SLU
  • 18.17. Johnson & Johnson
  • 18.18. Lepu Medical Technology (Beijing) Co., Ltd
  • 18.19. Medtronic plc
  • 18.20. Merit Medical Systems, Inc.
  • 18.21. MicroPort Scientific Corporation
  • 18.22. OrbusNeich Medical Company Limited
  • 18.23. Penumbra, Inc.
  • 18.24. Stryker Corporation
  • 18.25. Teleflex Incorporated
  • 18.26. Terumo Corporation
  • 18.27. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL REVASCULARIZATION DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL REVASCULARIZATION DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ATHERECTOMY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ATHERECTOMY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ATHERECTOMY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BARE-METAL STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BARE-METAL STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BARE-METAL STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-COATED BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-COATED BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-COATED BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY EVEROLIMUS-ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY EVEROLIMUS-ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY EVEROLIMUS-ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PACLITAXEL-ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PACLITAXEL-ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PACLITAXEL-ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY SIROLIMUS-ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY SIROLIMUS-ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY SIROLIMUS-ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ZOTAROLIMUS-ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ZOTAROLIMUS-ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ZOTAROLIMUS-ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY VASCULAR SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY VASCULAR SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY VASCULAR SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BIOABSORBABLE SCAFFOLD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BIOABSORBABLE SCAFFOLD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BIOABSORBABLE SCAFFOLD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY COBALT-CHROMIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY COBALT-CHROMIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY COBALT-CHROMIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PLATINUM-CHROMIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PLATINUM-CHROMIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY PLATINUM-CHROMIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BIORESORBABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BIORESORBABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY BIORESORBABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY SPECIALTY CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY SPECIALTY CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY RESTENOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY RESTENOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY RESTENOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY STABLE CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY STABLE CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY STABLE CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 174. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 176. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 177. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GCC REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 201. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 203. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 204. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 205. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. G7 REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 210. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 212. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 213. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 214. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA REVASCULARIZATION DEVICE MARKET SIZE, BY DRUG-ELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA REVASCULARIZATION DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA REVASCULARIZATION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA REVASCULARIZATION DEVICE MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA REVASCULARIZATION DEVICE MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA REVASCULARIZATION DEVICE MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)